Positive Interim 12-Week Results of ASC41 Trial Presented at EASL Congress 2024
Monday, 10 June 2024, 21:20
ASC41 Trial Results at EASL 2024
The recent presentation at EASL Congress 2024 highlighted the interim data from the Phase II clinical trial of ASC41 by Gannex.
Promising Outcomes for MASH Patients
The results showed significant improvements in patients with biopsy-confirmed MASH, indicating the potential effectiveness of ASC41 in addressing this condition.
- Positive trend: The findings demonstrated a positive trajectory towards meeting the medical needs of MASH patients.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.